#2848 Persistent albuminuria is a marker of persistent congestion in patients with chronic heart failure

Abstract

Abstract Background and Aims Albuminuria is prevalent in patients with heart failure (HF) and associated with poor prognosis. Initial reports indicate albuminuria as a congestion marker in HF. Frequency and associations of persistent albuminuria with kidney function, NT-proBNP and venous congestion in this population are not clearly understood. We aimed to evaluate the dynamics of albuminuria and its relationship with congestion and renal function in patients with chronic HF (CHF). Method The study included patients ≥18 years, observed in an outpatient HF center, who signed an informed consent. Patients receiving renal replacement therapy, with cancer or primary kidney diseases were excluded. The visits were carried out with an interval of 3 months. During each visit we performed routine physical examination, laboratory tests (NT-proBNP, urine albumin/creatinine ration (uACR), and serum creatinine) and pulse-wave Dopplerography to assess renal venous blood flow. Persistent albuminuria was defined as maintaining an uACR > 30 mg/g on two visits. Albuminuria level was assessed according to KDIGO guidelines 2012 (A1, A2, A3). The absence of venous congestion was defined as continuous renal blood flow, while venous congestion - as intermittent (biphasic or monophasic) blood flow. A P value <0.05 was considered statistically significant. We prospectively included 103 patients with CHF (46% male, mean age - 70 (61;75) Me (IQR) years, 53% with reduced ejection fraction (EF), mean EF 45(34;53)%, 92% hypertensive, 60% with atrial fibrillation, 34% with diabetes mellitus type 2, 51% with chronic kidney disease (CKD), 43% with coronary heart disease). Results Mean uACR values at the 1st visit was 18(8;56) mg/g, at the 2nd visit - 11(0;35) mg/g. The frequency of albuminuria levels at the 1st visit were A1-66%, A2-26%, A3-8%; at the 2nd visit – A1-73%, A2-23%, A3-4%. Persistent albuminuria was detected in 37 patients (36%). The mean values of albuminuria were higher in the persistent albuminuria group on the 1st visit (76(39;222) vs 10.5(0;19.5) for patients with and without persistent albuminuria, p<0.001) and on the 2nd visit (94(44;176) vs 7(0;13), p < 0.001). The patient groups were comparable in gender, age, frequency of comorbidities, EF. The administration of disease-modifying therapy was the same in the groups, however, the dose of loop diuretic was higher in the group of persistent albuminuria (20 (10;75) vs 10(5;20) mg respectively, p = 0.024 (doses in terms of furosemide)). Serum creatinine level was 95(79;121) mmol/l; GFR (CKD-EPI 2021)- 69(52;88) mL/min/ 1.73 m2 at the 1st visit. Kidney function did not statistically differ in the groups with and without persistent albuminuria (at the 1st visit eGFE - 63(52;87) vs 70 (50;90) mL/min/1.73 m2, p = 0.52 and the 2nd visit eGFR- 68(48;85) vs 66 (48;89) mL/min/1.73, p = 0.65 respectively). The level of NT-proBNP was higher in patients with persistent albuminuria during the 1st (926 (472;1820) vs 550(260;919), pg/ml p = 0.04) and the 2nd visit (1244(987;2000) vs 593(264;1405), pg/ml, p = 0.0008). Intermittent renal veins blood flow on the 2nd visit was observed in 26 patients (25%). In patients with persistent albuminuria persistence of intermittent venous renal blood flow was more frequently than in patients without it (43% vs 7%, p = 0.017, respectively). Figs. 1 and 2 demonstrate that renal venous congestion was more severe in group of persistent albuminuria on visit 1st and 2nd respectively. Conclusion Persistent albuminuria over 3 mounts in patients with stable chronic heart failure is associated with persisting congestion (higher NT-proBNP levels and higher incidence and severity of renal venous congestion). There was no association between changes in albuminuria and changes in renal function.